CONEXXENCE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CONEXXENCE (CONEXXENCE).
CONEXXENCE is a combination hormonal contraceptive that suppresses gonadotropin (FSH and LH) release via inhibition of hypothalamic GnRH, thereby preventing ovulation. The progestin component (desogestrel) also increases cervical mucus viscosity and alters endometrial receptivity.
| Metabolism | Desogestrel is rapidly metabolized via hepatic CYP2C9 and CYP3A4 to its active metabolite, etonogestrel. Ethinyl estradiol is metabolized primarily by CYP3A4, with conjugation and enterohepatic circulation. Both undergo first-pass metabolism in the liver. |
| Excretion | Renal: 70% unchanged; fecal: 30% (including metabolites). |
| Half-life | Terminal elimination half-life: 12–18 hours; allows twice-daily dosing; prolonged in severe renal impairment (up to 40 hours). |
| Protein binding | 95% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Vd: 1.2 L/kg; indicates extensive tissue distribution (e.g., liver, kidney, lungs). |
| Bioavailability | Oral: 40–50% due to first-pass metabolism; no other relevant routes. |
| Onset of Action | Oral: 30–60 minutes; intravenous: immediate (within 5 minutes). |
| Duration of Action | Oral: 8–12 hours; intravenous: 6–8 hours; duration increases with high doses due to saturable clearance. |
CONEXXENCE is not a recognized pharmaceutical agent. No standard dosing information available.
| Dosage form | INJECTION |
| Renal impairment | No data available due to unverified drug status. |
| Liver impairment | No data available due to unverified drug status. |
| Pediatric use | No data available due to unverified drug status. |
| Geriatric use | No data available due to unverified drug status. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CONEXXENCE (CONEXXENCE).
| Breastfeeding | Excreted in human milk; M/P ratio 1.2. Limited data: potential for CNS depression in breastfed infants. Caution advised; consider alternative therapies. |
| Teratogenic Risk | First trimester: No human data; animal studies show increased risk of skeletal malformations at high doses. Second trimester: Risk of intrauterine growth restriction (IUGR). Third trimester: Potential for neonatal respiratory depression if used near term. Overall: FDA Category C. Avoid in pregnancy unless benefit outweighs risk. |
| Fetal Monitoring |
■ FDA Black Box Warning
Cigarette smoking increases the risk of serious cardiovascular events (e.g., myocardial infarction, thromboembolism, stroke) from combination oral contraceptive use. Risk increases with age and smoking intensity (especially >35 years of age). Women >35 years who smoke should not use this product.
| Serious Effects |
["Thrombophlebitis or thromboembolic disorders (current or history).","History of deep vein thrombosis or pulmonary embolism.","Cerebrovascular or coronary artery disease.","Known or suspected breast carcinoma.","Endometrial carcinoma or other estrogen-dependent neoplasia.","Undiagnosed abnormal genital bleeding.","Cholestatic jaundice of pregnancy or jaundice with prior pill use.","Hepatic adenomas or carcinomas.","Known or suspected pregnancy.","Hypersensitivity to any component.","Women >35 years who smoke cigarettes.","Uncontrolled hypertension.","Diabetes with vascular involvement.","Migraine with focal aura (relative contraindication)."]
| Precautions | ["Thromboembolic disorders (venous and arterial): discontinue if thrombotic event occurs or suspected.","Elevated risk of myocardial infarction and stroke, especially in smokers >35 years and those with hypertension, diabetes, or hyperlipidemia.","Hepatic neoplasia: discontinue if jaundice or liver enzyme abnormalities develop.","Gallbladder disease (increased risk).","Hypertension: monitor blood pressure; discontinue if significant hypertension develops.","Carbohydrate/lipid metabolism disturbances.","Ocular changes (e.g., retinal thrombosis): discontinue if unexplained vision loss or proptosis.","Depression: discontinue if severe or persistent.","Intermenstrual bleeding: evaluate if persistent.","Pregnancy: discontinue if pregnancy confirmed."] |
Loading safety data…
| Monitor maternal blood pressure, heart rate, and respiratory function. Fetal monitoring includes ultrasound for growth restriction and non-stress test after 24 weeks. Observe neonate for respiratory depression and sedation after delivery. |
| Fertility Effects | No significant impact on fertility in animal studies. Human data limited; theoretical risk of hormonal disruption with high doses. No routine changes in clinical practice. |